MORF News and Press, Morphic Holding Inc. From 04/25/23

-In EMERALD-1 Phase 2a trial in patients with ulcerative colitis, MORF-057 meets primary endpoint and demonstrates clinically meaningful improvements across secondary and exploratory measures with no safety signal observed- -EMERALD-2 Phase 2b Trial of MORF-057 progressing on track- ...

2023-04-24 17:17:27 ET Gainers: Medpace Holdings ( MEDP ) +27% . Jupiter Wellness Acquisition  ( JWAC ) +4% . Rhythm Pharmaceuticals ( RYTM ) +3% . IDEAYA Biosciences ( IDYA ) +3% . Morphic Holding ( MORF ) +3% . Loser...

WALTHAM, Mass., April 24, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced it will host a webcast and conference call to discuss toplin...

2023-04-23 12:00:00 ET Biotech deal-making is on a roll, with more than $12B worth of transactions announced over the past week alone, and, according to industry observers, the trend is expected to continue in 2023, supported by macro and certain industry-specific factors. Days after Me...

WALTHAM, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that the EMERALD-2 phase 2b study of MORF-057 in ulcera...

WALTHAM, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Dr. Bruce Rogers, President of Morphic, will parti...

Morphic press release ( NASDAQ: MORF ): Q3 GAAP EPS of -$0.78 beats by $0.05 . Revenue of $2.05M (-34.3% Y/Y) misses by $1.05M . As of September 30, 2022, Morphic had cash, cash equivalents and marketable securities of $371.8 million, compared to $397.6 million...

Completed enrollment of EMERALD-1 phase 2a trial of MORF-057 in patients with ulcerative colitis ahead of schedule EMERALD-2 phase 2b global randomized study of MORF-057 to begin fourth quarter WALTHAM, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (...

Saturating receptor occupancy at 100 and 200 mg BID doses Statistically significant effects on key lymphocyte subsets WALTHAM, Mass., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral i...

WALTHAM, Mass., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced the completion of targeted enrollment of 30 patients ah...